Accelerating Toward the Clinic in 2025 Trogenix has successfully achieved all milestones in platform and asset development, positioning the company to enter the clinic in…
Read More
Trogenix comes out of stealth, unveiling its innovative Synthetic Super-Enhancers (SSE) platform, Odysseus, to develop highly selective, one-time cancer treatments. Equipped with £15 million ($19…
Read More
Trogenix has emerged from stealth to advance its pipeline of viral immunotherapies for cancer, starting with a lead candidate targeting an aggressive type of brain…
Read More
Company founded by 4BIO Capital and Professor Steve Pollard as a spinout from the University of Edinburgh to commercialise its breakthrough Synthetic Super-Enhancer platform, Odysseus,…
Read More
Trogenix recently hosted a landmark workshop at The Royal College of Surgeons in Edinburgh, uniting pioneering experts in neurosurgery, gene therapy, and oncology to advance…
Read More
Grant will accelerate development and evaluate Trogenix’s SSE technology in liver hepatocellular carcinoma and colorectal cancer liver metastases Edinburgh, UK, January 2024 - Trogenix Ltd…
Read More